BRAND conversation

711 views

Published on

The Notion: 5pt BRAND conversation is a brand conversation that is designed to engage consumers with products and services. Effective communication design creates a dialogue and encourages the consumer to start a conversation about their experience in the brand community.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
711
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

BRAND conversation

  1. 1. ! "#$%& ()*+,-./01)*communication design that starts a conversation CHRISTY SCHWINDT
  2. 2. ! "#$%& ()*+,-./01)*! Strategy + Opportunity 5pt BRAND conversation! Brand Mission The Mission: To design a brand that drives and motivates consumers. The Notion: 5pt BRAND conversation is a brand! conversation that is designed to engage consumers with Define Brand Community products and services. Effective communication design creates a dialogue and encourages the consumer to start a conversation about their experience in the brand! community. Develop Identity “To grow now, companies must innovate and perform on every level, and that is where design comes into play.” - Warren Berger! Communication Design
  3. 3. ! "#$%& ()*+,-./01)* Case Study: iC42 C42www.bioanalytics.us integrated solutions in systems biology clinical research & development
  4. 4. ! "#$%& ()*+,-./01)*! Strategy: To become a leader in bioanalytical services. Opportunity: Brand the service center and introduce it’s capabilities to the iC42 community. Case Study: iC42! Brand Mission: To serve science with integrated solutions to systems biology.! iC42 Brand Community University of Colorado Research Community C42 www.bioanalytics.us integrated solutions in systems biology clinical research & development Global Collaborations Novartis Siemens Thermofisher Kaiser Pain Clinics Toxicology Patients Vitamin D Patients Transplant Patients Pediatric Pharmacology! Develop Identity: Trademarked Brand : iC42 Trademarked Mark for Commerce Trademarked IP for iC42 Trademarked Colors: Custom Yellow, Gray & Black Typography: Myraid Pro
  5. 5. ! ! Communication Design: Business Cards "#$%& ()*+,-./01)* Case Study: iC42 C42 www.bioanalytics.us integrated solutions in systems biology clinical research & development •Highly Sensitive HPLC, LC-MS, GC-MS Bioanalytics •Complex Assay Development & Validation •GLP Compliant, CAP Accredited, CLIA Certi ed •Quanti cation of Drugs & Metabolites Uwe Christians, MD, PhD, MRQA •Isolation of Drug Metabolites & Structural ID Professor & Laboratory Director •Clinical Therapeutic Drug Monitoring •Complete PK/PD Package Managed Under One Roof SEND SAMPLES TO: •Molecular Marker Discovery, Quali cation Bioscience East, Suite 100 & Development 1999 North Fitzsimons Parkway •Consulting & Strategic Research Partnerships Aurora, CO 80045-7503 email: uwe.christians@ucdenver.edu phone: 303.724.5665 www.bioanalytics.us Communication Design: Highlights from 35 page Service Catalog C42 www.bioanalytics.us integrated solutions in systems biology clinical research & development C42 www.bioanalytics.us integrated solutions in systems biology clinical research & development 1.1 Quantitative Bioanalytical Methods Compound Matrix Sensitivity Instrument ADMA, Homocysteine, Arg Plasma 0.3 M API 4000 Quantitative Bioanalytical Methods Compounds Alfentanil Plasma 0.1 ng/mL API 5000 Aprotinin Tissue (Rat Kidney) 80 ng/mL ELISA Biolimus Blood, Tissue, Stents 0.05 ng/mL API 5000 Cyclosporine / Metabolites Blood 0.1-1.0 ng/mL API 5000 DMXB Plasma/Brains 0.1 ng/mL API 5000 Duet DNA Monocytes Ratio GC-MS Everolimus Blood 0.1 ng/mL API 5000 Felbamate CSF, Brain, Serum 0.1 ng/mL API 5000 Fentanyl Plasma 0.01 ng/mL API 4000 Free-Fatty Acids Plasma, Tissue, Blood 100 M GC-MS GSH Plasma 10 M API 4000 Glucocorticiods Plasma 0.1 ng/mL API 5000 [13C] Glucose Plasma 10 M GC-MS [13C] Glycerol Plasma 10 M GC-MS High Energy Phosphates Tissues 0.25 M API 4000 Summary of Services Isoprostanes Ketamine Ketarolac Plasma, Urine Blood Plasma 0.01 ng/mL 1.0 ng/mL 1.0 ng/mL API 5000 UPLC-MS/MS API 4000 Lamotrigine Plasma 1.0 ng/mL API 4000 Le unomide Blood 0.1 ng/mL API 5000 Lidocaine Plasma 0.5 ng/mL API 4000 Lovastatin Plasma 0.1 ng/mL API 5000 Metabolic Pro ling Plasma, Urine, Tissue _______ Exactive Morphine / Metabolites Plasma 0.25 - 2.5 ng/mL API 5000 MPA Plasma 1.0 ng/mL API 4000 Naltrexone Plasma 0.1 ng/mL API 5000 Nicotine Hair 0.1 ng/mL API 5000 Pravastatin Plasma 0.5 ng/mL API 4000 Phenytoin Plasma 0.1 ng/mL API 5000 PhIP Plasma / Microsomes 0.1 ng/mL API 4000 Bioscience East, Suite 100 Propofol Plasma 0.5 ng/mL API 4000 1999 North Fitzsimons Parkway Sirolimus Tissues / Blood 0.01 ng/mL API 4000 Aurora, CO 80045-7503 Steroid Hormones Plasma 0.1 ng/mL API 5000 303-724-5665 Tacrolimus / Metabolites Blood 0.1 ng/mL API 4000 Temsirolimus / Metabolites Blood 0.1 ng/mL Exactive Valproic Acid Serum 1.0 ng/mL GC/MS Summary of Bioanalytical Services Summary of Services iC42 Colorado, June 2010 iC42 Colorado, June 2010 Vitamin D and Metabolites Plasma 0.1 ng/mL API 5000 7
  6. 6. "#$%& ()*+,-./01)* ! Case Study: iC42 Communication Design: Email Announcements Communication Design: Student Program LetterDid you know that a comprehensive bioanalytics lab is available to you and is located on the University of Colorado’s Premier Medical Campus? C42www.bioanalytics.us integrated solutions in systems biology clinical research & development Welcome, we thank you for your interest in iC42. We are looking forward to supporting you and assisting you with your clinical trials as well as providing state-of the-art bioanalytical services. In addition, we are offering you world-class training in clinical research and development. At iC42, you will find abundant opportunities to participate in Highly Sensitive HPLC, LC-MS, GC-MS Bioanalytics clinical, translational and benchtop research activities. Complex Assay Development & Validation GLP Compliant, CAP Accredited, CLIA Certi ed SEND SAMPLES TO OR VISIT US AT: iC42 Clinical Research & Development is a regulatory compliant mass spectrometry laboratory (cGLP Quanti cation of Drugs & Metabolites Bioscience East, Suite 100 complaint, CAP accredited and CLIA certified) with currently 17 mass spectrometers and is part of the Isolation of Drug Metabolites & Structural ID 1999 North Fitzsimons Parkway Department of Anesthesiology. We are a unique clinical research and development facility that Clinical Therapeutic Drug Monitoring Aurora, CO 80045-7503 combines quantitative mass spectrometry (drugs, drug metabolites, other small molecules and large Complete PK/PD Package Managed Under One Roof molecules, endogenous compounds), metabolic and protein profiling technologies all under one roof. Molecular Marker Discovery, Quali cation & Development We are designed and uniquely qualified to carry out the bioanalytics for complex clinical trials involving drug quantification and molecular marker strategies. In addition, iC42 carries out research Consulting & Strategic Research Partnerships and development projects including: molecular marker discovery and qualification, translational research, strategy development and the identification of molecular mechanisms. Projects range from For more information or to schedule a lab tour please email: the development and validation of assays and strategies with only a few study samples and clinical therapeutic drug monitoring to serving as the central laboratory for phase III clinical trials with more christy.schwindt@ucdenver.edu than 50 clinical centers and more than ten thousand samples. In addition to research and bioanalytical services, activities include consulting and interactions with regulatory agencies. iC42 is committed to advancing individual medicine by examining the unique biology of an individual to assess truly personalized treatments. Other major foci are the evaluation of pediatric pharmacokinetics, the development of clinical management tools for pediatric patients, advancement in transplantation and drug metabolism. In addition, we promote and enhance research through the Colorado Center for Transplantation Care, Research and Education and the Colorado Center for the Advancement of Pediatric Pharmacology. For additional information please contact: Jaimie Henthorn 303-724-5663 jaimie.henthorn@ucdenver.edu and please visit us at www.bioanalytics.us Sincerely, Uwe Christians MD, PhD, MRQA iC42 Laboratory Director “Where the future is made today…” - Dr. Bunsen Honeydew
  7. 7. Communication Design: USB Business Cards "#$%& ()*+,-./01)* ! Case Study: iC42 C42 www.bioanalytics.us C42 www.bioanalytics.us SEND SAMPLES TO: Bioscience East, Suite 100 1999 North Fitzsimmons Parkway Aurora, CO 80045 (303) 724-5665 Communication Design: 8” x 8” Marketing Conference Cardspediatric pharmacokinetics Dr. Galinkin is a leader in the eld of Pediatric Pharmacology and Anesthesiology, he is a leader in pediatric research here at the University of Colorado. Internationally, Dr. Galinkin is recognized for his expertise in pediatric pharmacokinetics. He discover integrity intelligence innovation integrated solutions in systems biology Extensive Experience & Interactions with Small Biotech C42 clinical research & development integrated Solutions in Systems biology biotech pharmaceutical academia regularly lectures at international scienti c meetings and locally on drug pharmacokinetics. Companies He has designed and conducted many clinical studies in all stages of clinical development and We are a unique comprehensive facility that combines quantitative mass spectrometry, has served on multiple steering committees for multi center trials and for multiple contact Bench top-to-Bed Drug metabolic and protein pro ling technologies in a regulatory compliant environment. pharmaceutical company studies. Metabolism Studies We are designed and uniquely quali ed to carry out the bioanalytics for complex clinical trials involving drug quanti cation and molecular marker strategies. In C42 Locally, Dr. Galinkin is one of the Chairs of the IRB for the University of Colorado. He also co- Consulting & Strategic Research addition, iC42 carries out research and development projects including: molecular chairs the Scienti c Advisory Committee for the University of Colorado’s Clinical Translational Partnerships marker discovery & quali cation, translational research, strategy development and the Science Institute, a NIH funded vehicle that provides infrastructure to clinical investigators identi cation of molecular mechanisms. Projects range from the development and throughout the University. Additionally, Dr. Galinkin is the Chair of the Pharmacy and Complete Molecular Marker validation of bioanalytical assays and strategies to serving as the central bioanalytical Therapeutics Committee at The Children’s Hospital. Discovery, Quali cation & laboratory for phase III clinical trials with more than 50 clinical centers and more than contact us for... www.bioanalytics.us Development ten thousand samples. In addition to research and bioanalytical services, activities include consulting and interactions with regulatory agencies. design & conduct of Clinical Therapeutic Drug pediatric pharmacokinetics Monitoringpharmacogenomics pharmocokinetics pharmacodynamics phone: 303-724-5665 clinical trials in pediatric populations Novel Translational Technologies drug metabolism phase I clinical trials email: christy.schwindt@ucdenver.edu in a GLP-Compliant Environmenthighly sensitive LC/MS assays in low volume samples predictivedrug eluting stents biomarkers Complete PK/PD package in a regulatory compliant environment Managed “Under One Roof”bioanalytics in plasma samples & dry blood spots on lter paper visit us at Bioscience East, Suite 100 1999 N. Fitzsimons Parkway Complex Assay Developments & Validations metabolomicsdevelopment of new pain management strategiespopulation pharmacokinetics pediatric drug metabolism studies Aurora, CO 80045 High-Impact Publications & Presentations pk/pd studies proteomics www.bioanalytics.us isolation of drug metabolites !"##$%&#$(%()#*$+,($-.//0$1$2,34 phone: 303.724.5665 email: christy.schwindt@ucdenver.edu
  8. 8. Communication Design: Interior Signage ! "#$%& ()*+,-./01)* Case Study: iC42 C42www.bioanalytics.us integrated solutions in systems biology clinical research & development 50”w x 20”h Entry Wall color on clear vinyl 50” x 20” Entry Wall color on clear vinyldiscover integrated solutions in systems biology 15” diameter color LOGO on clear vinyl to be used on all (5) entry doors. Needs to be removable 20” diameter color LOGO on clear vinyl 15”w x 8”h Entry Door color on clear vinyl to be used on all (5) interior windows. Needs to be removable 15”width x 8”height color on clear vinyl
  9. 9. 5. Communication Design: Website "#$%& ()*+,-./01)* ! Case Study: iC42 When you roll over the logo with the cursor the i’s spins clockwiseiC42 Homepage Design 3/12/11 2:53 PM and our 3 key words pop out: individualized medicine, innovation, intelligence, Current logo individualized medicine innovation intelligence C42 www.bioanalytics.us integrated solutions in systems biology clinical research & development ! !!!!!!!! !!!!! LABORATORY REQUISITION SERVICE REQUESTED BY: !!!!!!!!!!!!!!!!!! BILLING INFORMATION: ! ! Name ! ! ! ! ! ! !! Name! ! ! ! ! ! ! ! ! ! ! ! Address ! Address ! Phone Phone Email ! ! Email ! ! ! ! ! Budget !! ! PROFORMA INVOICE WILL BE SENT ! ! ! SEND SAMPLES TO: CHECKLIST BEFORE SENDING SAMPLES: PO or Service Agreement accepted by iC42 iC42 Laboratory Samples Inventory (excel) emailed to iC42 before samples are shipped ATTN: SAMPLE DEPT Laboratory Requisition Form included with samples that are shipped Bioscience East, Suite 100 1999 Fitzsimons Pkwy all correspondence to uwe.christians@ucdenver.edu Aurora, CO 80045 ! phone 303-724-5665 ! ! SPECIMEN INFORMATION ! Routine!! Stat! # of Samples sent:!"""""""""""""""! ! Sample Matrix:! ! URINE! ! PLASMA ! SALIVA ! ! ! ! Storage Instructions:_________________________________ Freezer Location/Intials___________________(iC42) Test Requested:!!! ! Bioanalytical Analysis Vitamin D Therapeutic Panels Clinical Therapeutic Monitoring ! please specify: please specify: please specify: ! Additional test(s) requested: """"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""" ! !""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""" ! REPORTING INFORMATION ! ! ! ! ! ! ! ! ! ! EMAIL FAX OTHER Additional Report(s) to:!"""""""""""""""""""""""""""""""""""""! ! ! Please SEND Report(s) to: ! ! ! Phone: """"""""""""""""""""!!!Fax: """"""""""""""""""""! ! ! !
  10. 10. 5. Communication Design: Diagnostic Tool Product Launches ! "#$%& ()*+,-./01)* Case Study: iC42 i HyperION clinical research & development intelligent sample kits
  11. 11. !"#$%& ()*+,-./01)*Case Study: Book Illustrations
  12. 12. 4. Communication Design : Medical Book Illustrations Proteomics and the Kidney 105 Proteomics and the Kidney 107 Figure 4.1 Time-dependency of kidney tubular epithelium injury and molecular markers in urine.13,14 Injury will affect cell function before histological and patho- physiological damage can be detected. At an early point in the process, this is re ected in protein and metabolite patterns in urine, as absorption and excretion are altered, repair proteins are formed and cells release proteins into urine. The resulting extent of urine metabolite and protein pattern changes depends on the intensity of the injury and how many cells/tubules are affected. Proteins that have been found to be changed in urine and that may serve as early kidney injury markers are listed in Table 4.5 and are shown in Figure 4.4. As increasing numbers of cells die by necrosis and/or apoptosis, the biochemical phase of injury will progress towards the symptomatic phase. These cells will release at least some of their contents, such as metabolites, proteins, RNA and DNA, into the urine. Cell death will also trigger secondary reactions such as in am- mation and brosis. Once this occurs, a complete recovery may no longer be possible. The injury results in histological changes and kidney function will be reduced. It is not until the symptomatic phase that currently established diagnostic markers such as serum creatinine concentrations and blood urea nitrogen will signi cantly change. Figure 4.2 Proteomics sample analysis.17 Proteomics analysis is a multiple step procedure that typically involves sample preparation, pre-separation and/or digestion, During the biochemical stage, changes in gene expression, protein ionization, mass spectrometry analysis, protein identi cation, biostatistics and anno- expression and biochemical profiles occur, but the cells and organs are still tation. Proteomics strategies can be divided into ‘bottom up’ and ‘top down’ approaches. Bottom up approaches are most frequently used and involve digestion of able to compensate for this. At this stage, an injury process should be the proteins of interest and, after mass spectrometry analysis, identi cation of proteins detectable if sufficiently sensitive assays are available. During the bioche- using database searching based on the detected peptides. Top down proteomics does mical phase, no notable histological damage has occurred, and the disease not involve a digestion step and analyses the intact proteins. As discussed, both process may be fully reversible if an appropriate therapeutic intervention is strategies have their advantages and limitations. available.
  13. 13. Metabolomics and the Kidney 45 90 Uwe Christians, Jeska Albuisson, Jost Klawitter and Jelena Klawitter Figure 3.6 The role of metabolomics and metabolomics-derived combinatorial metabolite markers for individualized medicine and molecular epidemiology.Figure 3.1 Interactions between the mammalian system, the microbial metabolome,diet and environment.13 information into robust and meaningful clinical information. Another problem is that most of the hundreds and thousands of data points generateddefined as biological compounds that are generally hydrophobic in nature are not relevant to the disease or drug effect. Instead of conveying additionaland soluble in organic solvents. Lipids are membrane components, medi- information they only cause random statistical noise including falselyators in cell signaling and are utilized as fuel and energy storage.15 Their positive results and may mask valid information. However, while non-distinct solubility properties often require separate extraction and analysis in targeted ‘omics’ technologies are mostly hypothesis-generating technolo-metabolomics experiments.14 gies, this information is valuable to develop new targeted diagnostic The metabolome is considered the most predictive phenotype and holds strategies and tools.163the promise to extensively contribute to the understanding of phenotypic A ‘bottom up’ approach will start with metabolite markers alreadychanges as an organism’s answer to disease, genetic changes, and nutritional, established in clinical practice and will look at them not as single markers buttoxicological, environmental and pharmacological influences.4 Another will combine them into patterns. New markers that may have beenadvantage of metabolomics is that in contrast to genes and proteins, discovered using non-targeted metabolomics-based discovery may bemetabolites are often tissue- and species-independent. This facilitates added. This will result in the development of ‘combinatorial biomarkers’.translation of molecular markers strategies from bench-to-bedside or vice Those are molecular marker patterns that typically consist of 3e10 indi-versa,12 which is of advantage for drug development and molecular marker vidual parameters.164 In general, specific combinatorial biomarker patternsqualification (see below). Also, while it may take hours, days and sometimes confer significantly more information than a single measurement and, thus,weeks for protein and mRNA expression to change in response to a chal- can be expected to have better specificity and sensitivity than clinicallenge, metabolic responses can often be measured within seconds or chemical and biochemical markers currently used in nephrology. Suchminutes.4
  14. 14. 4. Communication Design : Medical Book Illustrations 108 Uwe Christians, Stephanie McCrery, Jost Klawitter and Jelena Klawitter Proteomics and the Kidney 111 Figure 4.3 Main proteomics strategies.2 The goal of comparative approaches is to detect differences between samples and, therefore, requires semi-quantitative comparison. Descriptive studies are usually qualitative and provide information about which proteins are present in a de ned sample. In either approach, study designs can Figure 4.4 Protein markers of kidney injury and their mapping to the nephron. be pathway- or non-pathway-driven. Pathway-driven studies are targeted e they focus Potential marker proteins frequently mentioned in the literature are shown. Thus, this on selected speci c pathways, a protein interaction network or a speci c sub- list should not be considered complete. The mapping represents the most abundant population of proteins. Some previous knowledge or a hypothesis is required. By locations; however, in the case of some proteins, this may be an over-simpli cation. For contrast, no prior biological knowledge is used in the design of non-pathway-driven or more information about these proteins, please see Table 4.5, page 142. non-targeted studies. Global analysis is undertaken (although steps are usually taken to reduce sample complexity) and the data generated can be regarded as hypothesis- generating. Most clinical protein marker discovery studies have been non-targeted and intracellular osmolyte concentrations (NUP88) and tight junction integrity comparative, and they identify proteins differing between study groups. Often such (MUPP1).22 As indicated, these distinct functions require the expression of studies do not produce protein identities, but generate algorithms to classify samples on the basis of protein separation pro les (‘ ngerprinting’). The output in descriptive specific sets of proteins. Exact knowledge of these distinct proteomes will not studies is a list of proteins. This list typically represents the catalogue of all proteins only allow for characterizing the type of injury and yield information detectable with a particular technology.2 regarding the associated mechanisms, but also for locating the injury. As shown in Figure 4.4, patterns of protein kidney injury markers can be Proteomics inherently is a hypothesis-generating discovery technology. mapped in the nephron. Proteomic studies can be classified as comparative studies that try to establish As urine can harbor proteins from all kidney subproteomes, and the quantitative or qualitative protein differences between samples and protein composition of urine is perturbed by kidney injury or disease, the descriptive studies that focus on the identification of proteins2 (Figure 4.3). urine proteome can subsequently signal the status of kidney health as well as In both cases, the study designs can be either pathway-driven (targeted) or
  15. 15. ! "#$%& ()*+,-./01)* Case Study: stephanie O. stephanie .stephanie O. logo white/Grey PDFSize: 6.6869” W x 1.7671” HTypeface: Raleway ThinColor: WhiteO logo: Grey, stroke .25
  16. 16. ! "#$%& ()*+,-./01)*! Strategy: To become a leader in Denver Fashion. stephanie O. to become a black label (custom line) and white label (ready-to-wear line). Opportunity: Black label start’s as a custom suiting line and the white label to be a high-fashion ready to wear travel collection. Once these have reached success, develop further by Case Study: stephanie O. introducing a bridal collection under the black label and fragrance line under the white label to compliment the stephanie O. brand conversation. ! Develop Identity: Brand: stephanie O. Colors: White, Black, Gray Typography: Raleway Thin! Brand Mission: Designs for the fashionable, modern woman! stephanie O. Community Black Label: Age Demographic: All ages Fashionable, Modern Women Successful Career Women stephanie . Collage Graduates Interviewing Brides Bridal Party Mother of the Bride Special Occasion White Label: Age Demographic stephanie O. logo white/Grey PDF Fashionable, Modern Women Size: 6.6869” W x 1.7671” H Travel Fashionista’a Typeface: Raleway Thin Color: White Weekend Fashionista’s O logo: Grey, stroke .25
  17. 17. ! Communication Design: Business Cards & Price Tags stephanie O. business card design layout and specifiations ! "#$%& ()*+,-./01)* Case Study: stephanie O.3 1/2” Business Card (front) stephanie O. design Size: 1.75” x 3.5” Typeface: Raleway Thin Logo: Custom O 5. Communication Design: Fashion Labels stephanie O. clothing label design specifications stephanie . 1 3/4” Clothing: Black Label Custom and Trunk Show Pieces stephanie . Size: 1.5”W x .5”H Typeface: Raleway Thin ready to wear fashion Business Card (back) Typeface Color: White stephanie O. design O logo color: Light Grey, stroke .25 Color background: Black Size: 1.75” x 3.5” Typeface: Raleway Thin Logo: Custom O Clothing: White Label stephanie . Ready to Wear Size: 1.5”W x .5”H Typeface: Raleway Thin Typeface Color: Black O logo color: Light Grey, stroke .25 stephanie Ohnmacht Color background: White 303.549.5320 stephanie@stephanieodesigns.com
  18. 18. !"#$%& ()*+,-./01)*Case Study: The Room Tailor
  19. 19. ! "#$%& ()*+,-./01)*! Strategy: To become a leader in Interior Design Consultation. Opportunity: Create a brand identity to compliment The Room Tailor, that attracts new business. Marketing design recommended: “At your Service” door hangers and custom design canvas totes for clients. Case Study: The Room Tailor ! Develop Identity: Brand: The Room Tailor Colors: Custom Typography: Pilo Thin! Brand Mission: “the art of living.”! The Room Tailor Community Homeowners selling their homes First time homebuyers Contractors Architects Interior Design Showrooms Real Estate Agents Wedding Planners
  20. 20. ! Communication Design: Business Cards ! "#$%& ()*+,-./01)* Case Study: The Room TailorBusiness CardsSize: 2.5” x 2.5” print 50 of each color the art of living the art of living the art of living the art of living the art of living Front Sideconni newsome conni newsome conni newsome conni newsome conni newsome 720.422.8235 720.422.8235 720.422.8235 720.422.8235 720.422.8235Backside
  21. 21. Communication Design: Postcard ! "#$%& ()*+,-./01)* Case Study: The Room Tailor the art of living
  22. 22. Communication Design: Custom Stamp & Ink Colors ! "#$%& ()*+,-./01)* Case Study: The Room Tailor Pantone Solid to Process 262 EC Pantone Process DS159-2C Pantone Metallic Coated 877 C Pantone Color Bridge CMYK EC 2955 EC Pantone Solid Matte 124 M
  23. 23. !"#$%& ()*+,-./01)*Case Study: Blues
  24. 24. ! "#$%& ()*+,-./01)*! Strategy: To become a leader in creative concept development. Opportunity: Target the tea and coffee industry. Case Study: The Room Tailor ! Develop Identity: Brand: Blues Colors: Custom Typography: Optima! Brand Mission: creative + concept + development! Blues Community Tea Cafe’s Coffee Cafe’s Small Business Start Up’s Tea & coffee product development Retail
  25. 25. ! Communication Design: Creative Concept Development Menu "#$%& ()*+,-./01)* ! Case Study: Blues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choose blues, contact Paul at 303- 775-3856

×